-
Posted by
Two Blokes May 16 -
Filed in
Stock
-
1 view
The company delivered 45% revenue growth in Q1 2025, driven by ZEPBOUND and MOUNJARO's strong performance in the obesity and diabetes markets. ZEPBOUND outperformed Novo Nordisk's WEGOVY in terms of weight loss, solidifying Lilly's leadership in the booming global anti-obesity drug market space. The company's oral GLP-1 agonist orforglipron showed promising phase 3 results, positioning the company ahead of competitors in T2D and possibly the obesity drug treatment space.
